RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Stock Short Interest Climbs 205.4%

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) saw a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 623 shares, an increase of 205.4% from the August 31st total of 204 shares. Based on an average daily volume of 196 shares, the short-interest ratio is presently 3.2 days. Currently, 0.1% of the shares of the company are sold short.

RCN Pareto Strategic Allocation ETF Price Performance

Shares of PRTO stock traded up $0.07 during trading on Friday, reaching $27.58. 311 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $27.84. The company has a market capitalization of $17.38 million, a P/E ratio of -28.73 and a beta of 1.07. RCN Pareto Strategic Allocation ETF has a 1 year low of $24.68 and a 1 year high of $28.58.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.